Cargando…

Need for optimized dosages in the design of comparative clinical trials of anti-malarial drugs

We read with interest the publication on malaria treatment by Obonyo et al. (Malaria J 21:30, 2022). This commentary questions the methodology, especially the chosen time points of treatment outcome measures.

Detalles Bibliográficos
Autores principales:	Krishna, Sanjeev, Kremsner, Peter G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208120/ https://www.ncbi.nlm.nih.gov/pubmed/35725411 http://dx.doi.org/10.1186/s12936-022-04170-1

Ejemplares similares

Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria
por: Nguetse, Christian N., et al.
Publicado: (2017)

In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays
por: Kurth, Florian, et al.
Publicado: (2009)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020)

Regulating new drugs in India needs to be improved
por: Roderick, Peter
Publicado: (2023)

Towards optimal design of anti-malarial pharmacokinetic studies
por: Simpson, Julie A, et al.
Publicado: (2009)

Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa
por: Slavic, Ksenija, et al.
Publicado: (2011)

The Need for a Cheap and Efficient Anti-Malarial Drug in India
Publicado: (1941)

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
por: Robinson, Philip C, et al.
Publicado: (2020)

Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic
por: Wang, Jigang, et al.
Publicado: (2020)

Anti-malarial Drug Design by Targeting Apicoplasts: New Perspectives
por: Mukherjee, Avinaba, et al.
Publicado: (2016)

Socially optimal pandemic drug dosing
por: Strohbehn, Garth W, et al.
Publicado: (2021)

Designing circulating tumor DNA-based interventional clinical trials in oncology
por: Araujo, Daniel V., et al.
Publicado: (2019)

Prevalence Studies on CKDu Need Stringent Reporting on Outcomes to Enhance Comparability
por: Jakobsson, Kristina, et al.
Publicado: (2020)

The 2022 monkeypox outbreak: the need for clinical curiosity
por: Gordon, N Claire, et al.
Publicado: (2023)

Artemisinin anti-malarial drugs in China
por: Guo, Zongru
Publicado: (2016)

The importance of dosage for naltrexone treatment in Hailey-Hailey disease
por: Grolleau, Chloé, et al.
Publicado: (2022)

Pulpotomy versus root canal treatment in permanent teeth with spontaneous pain: comparable clinical and patient outcomes, but insufficient evidence
por: Afrashtehfar, Kelvin I., et al.
Publicado: (2023)

Non-steroidal anti-inflammatory drug use in COVID-19
por: Kragholm, Kristian, et al.
Publicado: (2021)

Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials
por: Moran, Ed, et al.
Publicado: (2021)

The growing need for controlled data access models in clinical proteomics and metabolomics
por: Keane, Thomas M., et al.
Publicado: (2021)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against
por: Krishna, Sanjeev
Publicado: (2019)

Metal-chloroquine derivatives as possible anti-malarial drugs: evaluation of anti-malarial activity and mode of action
por: Navarro, Maribel, et al.
Publicado: (2014)

Susceptibility of human Plasmodium knowlesi infections to anti-malarials
por: Fatih, Farrah A, et al.
Publicado: (2013)

Substandard anti-malarial drugs in Burkina Faso
por: Tipke, Maike, et al.
Publicado: (2008)

The role of anti-malarial drugs in eliminating malaria
por: White, Nicholas J
Publicado: (2008)

Spectrophotometric detection of susceptibility to anti-malarial drugs
por: Serebrennikova, Yulia M, et al.
Publicado: (2013)

Note on Economy in the Use of Anti-Malarial Drugs
por: Covell, G.
Publicado: (1942)

Rapid diagnostics urgently needed for killer infections
por: Zumla, Alimuddin, et al.
Publicado: (2013)

Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs
por: Singh, Neera, et al.
Publicado: (2009)

The Dosage of Anti-Tetanic Serum
por: Iyer, M. A. Krishna
Publicado: (1925)

Why we need a single independent international hypertension clinical practice guideline
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2021)

Modulating effects of plasma containing anti-malarial antibodies on in vitro anti-malarial drug susceptibility in Plasmodium falciparum
por: Monatrakul, Preeyaporn, et al.
Publicado: (2010)

Care coordination in pediatrics: Experience of the outpatient clinic for Children with Special Health Care Needs (CSHCN)
por: Ferrer, Ana Paula Scoleze, et al.
Publicado: (2022)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
por: Mombo-Ngoma, Ghyslain, et al.
Publicado: (2011)

The Need for the Term "Malarial Cachexia"
Publicado: (1898)

Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate
por: Matthews, Holly, et al.
Publicado: (2013)

Contextualizing Appalachian health needs
por: Cronin, Cory E.
Publicado: (2023)

Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds
por: Tam, Dao Ngoc Hien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fntmveo287q79tegqb42b8hi32